SynthyraThe Platform
SystemsBiology
inaSecond.
Synthyra maps the full landscape of protein interactions, revealing the biological networks behind disease, defense, and drug safety.
The Problem
Biology knows the parts. The connections are what's missing.
The human proteome contains over 400 million possible protein interactions. We understand individual proteins well, and even many pairwise relationships. But mapping the full network of interactions at scale, in seconds, has been impossible. Until now.
0%
of drugs fail clinical trials
0M+
possible interactions in human proteome
$0M+
average cost of late-stage failure
The Engine
SYNTERACT
A protein language model that predicts protein-protein interactions at proteome scale.
Proteome-Scale
Screen against all 20,000+ human proteins in a single query
Real-Time
375 million interactions per second
Validated
AUROC 0.82 with wet-lab confirmed designs
Speed
The 2-Second Proteome.
While AlphaFold-Multimer would take over 7,600 years to screen the full human interactome, SYNTERACT completes it in seconds.
AlphaFold-Multimer
7,600 Years
SYNTERACT
~2 Seconds
0M
interactions per second
0x
faster than structure-based
~2s
full human proteome
Value
Three pillars. One platform.
Faster Cures
Accelerate target validation and lead optimization by screening against the full human interactome before wet-lab synthesis.
Discovery & Design Suite
Rapid Defense
Map how pathogen proteins interact with the human proteome in hours, not months. Enable rapid countermeasure development.
Biodefense Suite
Safer Drugs
Predict off-target interactions and toxicity risks across the full proteome before clinical trials begin.
Safety & Toxicity Suite
Solutions
Purpose-built product suites.
Validation
Built on evidence. Verified in the lab.
Independent benchmarks, third-party wet-lab validation, and millions of open-source downloads.
0.73
AUROC: Independent PPI benchmark
Bernett PPI benchmark dataset
+10%
MCC vs gold-standard methods
Matthews Correlation Coefficient, standard benchmark
0.69–0.72
AUROC: 5 species, no accuracy loss
Human, mouse, yeast, fruit fly, E. coli
0
AUROC: Core PPI prediction
Internal held-out validation, clustered splits
0
Novel interactors confirmed
BLI validation, Adaptyv Bio (third-party)
1.3M+
Model downloads
Open-source, global researcher adoption
Binding visualization
EGFR Binder Case Study
Wet-Lab ConfirmedSynthyra designed a variant of cetuximab, a multi-billion dollar cancer therapeutic, with 87% stronger binding affinity to EGFR (1.1 nM Kd). 13 designs tested, all improved vs controls, 6 achieved sub-3 nM binding.
Biolayer Interferometry on recombinant targets, SDS-PAGE QC. Adaptyv Bio
Ready to see the full picture?
Request access to SYNTERACT and map your proteome in seconds, not years.
or reach out at [email protected]